These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7037870)

  • 1. Clinical Pharmacology for Pediatricians. II. Antisickling agents, with special reference to new vasoerythroactive drugs.
    Cho YW; Aviado DM
    J Clin Pharmacol; 1982 Jan; 22(1):1-13. PubMed ID: 7037870
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of hydroxyurea in sickle cell disease.
    Halsey C; Roberts IA
    Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
    [No Abstract]   [Full Text] [Related]  

  • 4. Sickle cell anemia. Pathophysiology and treatment.
    Alavi JB
    Med Clin North Am; 1984 May; 68(3):545-56. PubMed ID: 6205230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane modifiers in sickle cell disease.
    Benjamin LJ
    Ann N Y Acad Sci; 1989; 565():247-61. PubMed ID: 2672964
    [No Abstract]   [Full Text] [Related]  

  • 7. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sickle cell anemia and related hemoglobinopathies.
    Vichinsky EP; Lubin BH
    Pediatr Clin North Am; 1980 May; 27(2):429-47. PubMed ID: 6155657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease.
    Abdulmalik O; Ataga KI
    EBioMedicine; 2017 Oct; 24():26-27. PubMed ID: 28890145
    [No Abstract]   [Full Text] [Related]  

  • 10. A view of the current status of antisickling therapy.
    Brewer GJ
    Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 12. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 13. Sickle-cell disease: Two new therapeutic strategies.
    Nalbandian RM; Henry RL; Murayama M
    Lancet; 1978 Sep; 2(8089):570-1. PubMed ID: 79930
    [No Abstract]   [Full Text] [Related]  

  • 14. [Orbital subperiosteal hematoma in child with sickle cell thalassemia. A case report].
    Douira-Khomsi W; Jarraya M; Ben Hassine L; Louati H; Chebbi A; Lahmar L; Bouguila H; Bellagha I
    Arch Pediatr; 2010 Aug; 17(8):1174-7. PubMed ID: 20452192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sickling process in relation to clinical manifestations.
    Bellingham AJ
    J Clin Pathol Suppl (R Coll Pathol); 1974; 8():23-5. PubMed ID: 4536364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
    Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
    Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK; Kato GJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia.
    Berkowitz LR; Orringer EP
    Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
    J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.